Contineum Therapeutics, Inc. CTNM
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -20.91%
- 1 year
- -27.27%
5D -1.26 (-12.00%)
- Market cap
- 354.96M
- EPS (ttm)
- -1.77
- Shares out
- 19.05M
- Forward P/E
- -7.68
- YTD return
- -20.91%
- 1-year return
- -27.27%
- 50-day average
- 15.77
- Volume
- 197.70K
- Avg volume
- 777.72K
- Open
- 9.31
- Previous close
- 9.24
- Day's range
- 8.93 – 9.63
- 52-week range
- 6.73 – 17.79
- Price target
- 29.25 (+223.6%)
Key statistics
- 200-day average
- 17.15
- Enterprise value
- 134.70M
- Price / book
- 1.73
- Free cash flow
- -22.27M
- Total cash
- 213.91M
- Total debt
- 611.00K
- Return on equity
- -20.76%
Fundamental scorecard
4 of 25 checks passed on CTNM’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2025 | Dec 1, 2024 | -0.44 | — | — | — |
| Nov 6, 2024 | Sep 1, 2024 | -0.41 | -0.40 | +0.01 | +2.44% |
| Aug 13, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.37 | -0.39 | -0.02 | -5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2024 | Baird | init | — | Outperform |
| Aug 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Apr 30, 2024 | RBC Capital | init | — | Outperform |
| Apr 30, 2024 | Stifel | init | — | Buy |
| Apr 30, 2024 | Morgan Stanley | init | — | Overweight |
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- contineum-tx.com
News
Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial Contineum Therapeutics Q3 EPS $(0.49) Misses $(0.45) Estimate
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Why Is Contineum Therapeutics Stock Falling Monday?
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Your note
Sign in to keep a note on CTNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUHN STEPHEN L | Officer | Conversion of Exercise of derivative security | Aug 12, 2024 | 12,800 |
| LORRAIN DANIEL S. PH.D. | Officer | Sale | Nov 24, 2024 | 172,460 |
| VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 10.39% | 1,979,173 | 27.99M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 9.03% | 1,720,000 | 24.32M | Sep 29, 2024 |
| Perceptive Advisors Llc | 7.96% | 1,516,668 | 21.45M | Sep 29, 2024 |
| Franklin Resources, Inc. | 7.60% | 1,447,550 | 20.47M | Sep 29, 2024 |
| Versant Venture Management, LLC | 4.82% | 918,163 | 12.98M | Sep 29, 2024 |
| Sectoral Asset Management, Inc. | 4.20% | 800,887 | 11.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.69% | 512,025 | 7.24M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.57% | 299,583 | 4.24M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.39% | 264,800 | 3.74M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.05% | 200,000 | 2.83M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 0.75% | 142,871 | 2.02M | Oct 30, 2024 |
| Fidelity Advisor Health Care Fund | 0.67% | 128,000 | 1.81M | Oct 30, 2024 |
